Our data indicate that genetic deletion or pharmacological inhibition of COX-2 reduces MMP-9 production in stroke, which reveals for the first time that COX-2 activity may contribute to MMP-9 expression and activation in the ischemic brain, and the resulting BBB damage. The gene discussed is MMP9; the disease is stroke disorder.